Lucid Diagnostics Inc. (LUCD) shareholders
Close on Nov 17, 2026Market cap $81.09MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| PAVmed Inc. | 38,816,903 | 27.50% | 13D (active) amendment | Feb 3, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LUCD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 8,856,844 | 4.36% | $9.48M | New | 0.02% |
| BlackRock, Inc. | 8,373,117 | 4.12% | $8.96M | +3,734,874 | 0.00% |
| Vanguard Capital Management LLC | 6,556,344 | 3.23% | $7.02M | +2,401,574 | 0.00% |
| Two Seas Capital LP | 6,000,000 | 2.95% | $6.42M | +3,000,000 | 0.13% |
| Masters Capital Management LLC | 4,000,000 | 1.97% | $4.28M | – | 0.11% |
| abrdn plc | 3,822,997 | 1.88% | $4.09M | +178,720 | 0.01% |
| Geode Capital Management, LLC | 3,789,948 | 1.86% | $4.06M | +1,544,598 | 0.00% |
| State Street Corp | 2,437,337 | 1.20% | $2.61M | +882,756 | 0.00% |
| First Manhattan Co. LLC. | 2,188,550 | 1.08% | $2.34M | +1,865,100 | 0.01% |
| Wells Fargo & Company/Mn | 2,067,046 | 1.02% | $2.21M | +792,656 | 0.00% |
| Russell Investments Group, Ltd. | 1,651,788 | 0.81% | $1.77M | +68,180 | 0.00% |
| Northern Trust Corp | 1,219,879 | 0.60% | $1.31M | +549,294 | 0.00% |
| Perkins Capital Management Inc | 1,125,000 | 0.55% | $1.20M | −1,000 | 0.91% |
| Vanguard Fiduciary Trust Co | 1,068,109 | 0.53% | $1.14M | +444,552 | 0.00% |
| Vanguard Portfolio Management LLC | 1,022,262 | 0.50% | $1.09M | +493,493 | 0.00% |
| UBS Group AG | 845,314 | 0.42% | $904.49K | +399,835 | 0.00% |
| Aqr Capital Management LLC | 723,200 | 0.36% | $773.82K | +488,431 | 0.00% |
| Raymond James Financial Inc | 577,381 | 0.28% | $617.80K | +52,445 | 0.00% |
| Lido Advisors, LLC | 446,739 | 0.22% | $478.01K | +63,657 | 0.00% |
| Charles Schwab Investment Management Inc | 325,312 | 0.16% | $348.08K | +127,888 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 116 | 61M | 30.2% | 25 / 59 | 13 / 10 | 28M | 1M |
| Q1 2026 | 103 | 36M | 17.5% | 26 / 32 | 19 / 11 | 10M | 2M |
| Q4 2025 | 89 | 32M | 15.8% | 18 / 30 | 16 / 14 | 5M | 8M |
| Q3 2025 | 86 | 35M | 17.3% | 25 / 31 | 11 / 11 | 17M | 1M |
| Q2 2025 | 72 | 19M | 9.3% | 32 / 19 | 6 / 9 | 12M | 3M |
| Q1 2025 | 49 | 9M | 4.6% | 20 / 12 | 8 / 4 | 7M | 1M |
| Q4 2024 | 33 | 3M | 1.6% | 11 / 8 | 8 / 6 | 1M | 0M |
| Q3 2024 | 29 | 2M | 1.2% | 5 / 6 | 8 / 9 | 1M | 0M |
| Q2 2024 | 34 | 2M | 1.0% | 8 / 9 | 8 / 4 | 0M | 0M |
| Q1 2024 | 30 | 2M | 1.0% | 9 / 11 | 8 / 4 | 1M | 0M |
| Q4 2023 | 25 | 2M | 0.9% | 3 / 7 | 7 / 1 | 0M | 0M |
| Q3 2023 | 24 | 2M | 0.9% | 7 / 4 | 5 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
68 funds held LUCD in Q2 2026, 75% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LUCD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,547,002 | 2.24% | $4.87M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,567,505 | 1.76% | $3.82M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,861,414 | 0.92% | $1.99M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,578,431 | 0.78% | $1.38M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,396,456 | 0.69% | $1.49M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 507,380 | 0.25% | $522.60K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 497,964 | 0.25% | $532.82K | 0.04% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 459,876 | 0.23% | $473.67K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 362,863 | 0.18% | $316.27K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 277,964 | 0.14% | $297.42K | 0.00% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 195,065 | 0.10% | $170.02K | 0.00% | Jul 31, 2026 |
| U.S. Small Cap Equity Fund | 186,569 | 0.09% | $162.61K | 0.02% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 171,254 | 0.08% | $176.39K | 0.00% | May 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 154,902 | 0.08% | $165.75K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 140,008 | 0.07% | $144.21K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lishan Aklog | Chief Executive Officer, Director | 3,636,627 | 1.79% | Feb 24, 2026 |
| Victoria Tou-ho Lee | Chief Medical Officer | 650,000 | 0.32% | Apr 24, 2026 |
| Dennis M. McGrath | Chief Financial Officer | 1,813,569 | 0.89% | Feb 24, 2026 |
| Shaun O'Neil | President and COO | 1,446,763 | 0.71% | Feb 24, 2026 |
| Michael Adam Gordon | General Counsel and Secretary | 1,000,000 | 0.49% | Feb 24, 2026 |
| Dennis Matheis | Director | 1,033,443 | 0.51% | May 21, 2026 |
| Debra White | Director | 235,800 | 0.12% | Feb 24, 2026 |
| James L. Cox | Director | 405,120 | 0.20% | Feb 24, 2026 |
| Ronald M. Sparks | Director | 320,460 | 0.16% | Feb 24, 2026 |
| John R. Palumbo | Director | 338,000 | 0.17% | Feb 24, 2026 |
| Stanley Lapidus | Director | 337,392 | 0.17% | Feb 24, 2026 |
| Jacque J. Sokolov | Director | 320,460 | 0.16% | Feb 24, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dennis Matheis Director | May 20, 2026 | Buy | +245,000 | $1.00 | $245.00K | 1,033,443 |
| Ronald M. Sparks Director | Feb 20, 2026 | Award | +123,000 | – | – | 320,460 |
| James L. Cox Director | Feb 20, 2026 | Award | +123,000 | – | – | 405,120 |
| Lishan Aklog Chief Executive Officer, Director | Feb 20, 2026 | Award | +2,170,000 | – | – | 3,636,627 |
| John R. Palumbo Director | Feb 20, 2026 | Award | +123,000 | – | – | 338,000 |
| Debra White Director | Feb 20, 2026 | Award | +123,000 | – | – | 235,800 |
| Dennis M. McGrath Chief Financial Officer | Feb 20, 2026 | Award | +470,000 | – | – | 1,813,569 |
| Jacque J. Sokolov Director | Feb 20, 2026 | Award | +123,000 | – | – | 320,460 |
| Shaun O'Neil President and COO | Feb 20, 2026 | Award | +620,000 | – | – | 1,446,763 |
| Stanley Lapidus Director | Feb 20, 2026 | Award | +123,000 | – | – | 337,392 |
| Michael Adam Gordon General Counsel and Secretary | Feb 20, 2026 | Award | +300,000 | – | – | 1,000,000 |
| Dennis Matheis Director | Feb 20, 2026 | Award | +123,000 | – | – | 788,443 |
| Dennis Matheis Director | Aug 20, 2025 | Buy | +100,000 | $1.02 | $102.00K | 665,443 |
| Dennis Matheis Director | May 22, 2025 | Buy | +33,218 | $1.32 | $43.85K | 565,443 |
| Dennis Matheis Director | May 22, 2025 | Buy | +33,218 | $1.32 | $43.85K | 350,000 |
| Dennis Matheis Director | May 21, 2025 | Buy | +129,684 | $1.32 | $171.18K | 532,225 |
| Dennis Matheis Director | May 21, 2025 | Buy | +129,684 | $1.32 | $171.18K | 316,782 |
| Dennis Matheis Director | May 20, 2025 | Buy | +187,098 | $1.30 | $243.23K | 402,541 |
| Dennis Matheis Director | May 20, 2025 | Buy | +187,098 | $1.30 | $243.23K | 187,098 |
| Shaun O'Neil President and COO | Feb 20, 2025 | Award | +300,000 | – | – | 826,763 |
| James L. Cox Director | Feb 20, 2025 | Award | +112,800 | – | – | 282,120 |
| Debra White Director | Feb 20, 2025 | Award | +112,800 | – | – | 112,800 |
| Dennis M. McGrath Chief Financial Officer | Feb 20, 2025 | Award | +300,000 | – | – | 1,343,569 |
| Michael Adam Gordon General Counsel and Secretary | Feb 20, 2025 | Award | +300,000 | – | – | 700,000 |
| Dennis Matheis Director | Feb 20, 2025 | Award | +112,800 | – | – | 162,725 |
| Ronald M. Sparks Director | Feb 20, 2025 | Award | +112,800 | – | – | 197,460 |
| Lishan Aklog Chief Executive Officer, Director | Feb 20, 2025 | Award | +300,000 | – | – | 1,466,627 |
| Jacque J. Sokolov Director | Feb 20, 2025 | Award | +112,800 | – | – | 197,460 |
| Stanley Lapidus Director | Feb 20, 2025 | Award | +112,800 | – | – | 214,392 |
| Shaun O'Neil President and COO | May 7, 2024 | Award | +400,000 | – | – | 526,763 |
| Lishan Aklog Chief Executive Officer, Director | May 7, 2024 | Award | +400,000 | – | – | 1,166,627 |
| Michael Adam Gordon General Counsel and Secretary | May 7, 2024 | Award | +400,000 | – | – | 400,000 |
| Dennis M. McGrath Chief Financial Officer | May 7, 2024 | Award | +400,000 | – | – | 1,043,569 |
| Inc. PAVmed 10% owner | Feb 15, 2024 | Other | −3,331,747 | – | – | 31,302,444 |
| Inc. PAVmed 10% owner | Jan 26, 2024 | Other | +3,331,771 | $1.40 | $4.66M | 34,634,191 |
| Stanley Lapidus Director | Sep 26, 2023 | Sale(10b5-1 plan) | −9,747 | $1.45 | $14.13K | 101,592 |
| Stanley Lapidus Director | Sep 26, 2023 | Sale(10b5-1 plan) | −10,000 | $1.43 | $14.30K | 111,339 |
| Stanley Lapidus Director | Sep 26, 2023 | Sale(10b5-1 plan) | −10,000 | $1.47 | $14.70K | 121,339 |
| Stanley Lapidus Director | Sep 25, 2023 | Sale(10b5-1 plan) | −200 | $1.43 | $286 | 131,339 |
| Stanley Lapidus Director | Sep 21, 2023 | Sale(10b5-1 plan) | −100 | $1.44 | $144 | 131,539 |
| Stanley Lapidus Director | Sep 21, 2023 | Sale | −100 | $1.44 | $144 | 131,539 |
| Stanley Lapidus Director | Sep 20, 2023 | Sale(10b5-1 plan) | −3,405 | $1.45 | $4.94K | 132,051 |
| Stanley Lapidus Director | Sep 20, 2023 | Sale(10b5-1 plan) | −412 | $1.44 | $593 | 131,639 |
| Stanley Lapidus Director | Sep 20, 2023 | Sale | −3,405 | $1.45 | $4.94K | 132,051 |
| Stanley Lapidus Director | Sep 20, 2023 | Sale | −412 | $1.44 | $593 | 131,639 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +1,479,326 | $1.84 | $2.72M | 31,302,420 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +331,210 | $1.66 | $549.81K | 29,823,094 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +221,952 | $2.48 | $550.44K | 29,491,884 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +1,145,086 | $1.84 | $2.11M | 29,072,276 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +197,656 | $2.78 | $549.48K | 29,269,932 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +221,952 | $2.48 | $550.44K | 40,672,939 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +331,210 | $1.66 | $549.81K | 41,004,149 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +1,479,326 | $1.84 | $2.72M | 42,483,475 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +197,656 | $2.78 | $549.48K | 40,450,987 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +1,145,086 | $1.84 | $2.11M | 40,253,331 |
| Stanley Lapidus Director | Sep 20, 2022 | Sale | −16,864 | $1.70 | $28.67K | 135,456 |
| Stanley Lapidus Director | Sep 20, 2022 | Sale | −17,000 | $1.71 | $29.07K | 152,320 |
| Lishan Aklog Chief Executive Officer, Director | Jan 7, 2022 | Award | +60,000 | – | – | 624,400 |
| Dennis M. McGrath Chief Financial Officer | Jan 7, 2022 | Award | +60,000 | – | – | 624,400 |
| Inc. PAVmed 10% owner | Oct 18, 2021 | Buy | +571,428 | $14.00 | $8.00M | 27,927,190 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lucid Diagnostics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 85,636 shares on Sep 10, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stanley Lapidus Director | Sep 26, 2023 | 33,864 | $49.10K | Sep 26, 2023 | Restricted Stock Grant under Board-Approved Issuer Plan |
See a number that looks wrong?